Zomato co-founder Deepinder Goyal has opened pre-orders for 'Temple', a new head-worn health device priced at ₹85,000. While the launch triggered high web traffic, the venture faces market skepticism regarding the high price point and the founder's transition from food delivery to premium scientific hardware.
Deepinder Goyal, the co-founder of Zomato, has officially entered the wearable technology market with the launch of his new venture, 'Temple'. Pre-orders for the device opened on November 1, 2026, marking a distinct shift from his primary focus on the food delivery and quick-commerce sectors. The product, a head-worn sensor designed to track cerebral blood flow and cognitive physiological strain, is positioned as a premium wellness tool.
The device uses optical sensors to measure what the company calls 'BrainFlow'—a proprietary way of tracking blood flow patterns in the brain. It assigns users an 'Entropy' score, ranging from 1 to 250, intended to quantify total physiological strain based on factors like sleep, physical exertion, and stimulant consumption. Crucially, the company has clarified that Temple is designed as a wellness and research tool rather than a medical diagnostic instrument, a distinction that is significant for potential users and market analysts assessing the device’s capabilities.
With a price tag of ₹85,000, which includes a lifetime subscription, the product has sparked considerable debate. Market observers are questioning whether the hardware features truly justify such a premium valuation. This skepticism is compounded by the challenge of brand identity. While Goyal is widely recognized for scaling Zomato, observers are debating whether consumers will trust a technology brand from a founder best known for food logistics. The brand's ability to decouple itself from the Zomato identity while proving the functional worth of its hardware is a central point of discussion.
From an operational perspective, Temple is using a made-to-order manufacturing model, with deliveries expected within approximately three months of purchase. This approach may help manage inventory costs, but it also creates potential risks regarding production delays and scaling bottlenecks. Additionally, since the device is an emerging health technology, it currently lacks long-term clinical validation for its proprietary metrics, which is a common hurdle for new health-tech products.
For those monitoring the venture, the key indicators will be the actual product delivery timelines, user reception of the 'Entropy' score, and whether the company can sustain its premium positioning as early adopters provide feedback. The initial website traffic, which led to temporary instability, indicates strong public interest, but long-term success will likely depend on whether the device can deliver tangible wellness insights that justify its high entry price.